ABOS · Acumen Pharmaceuticals, Inc.

Acumen’s Q1 2026 financial results reflect a deliberate operational pivot following completion of ALTITUDE-AD enrollment in March 2025: R&D expenses declined 35% year-over-year to $16.5 million, primarily due to reduced CRO and manufacturing costs, directly driving the $8.1 million improvement in net loss. The $11.5 million increase in cash, cash equivalents and marketable securities — from $116.9 million to $128.4 million — was explicitly attributed to the March 2026 private placement ($35.75 million gross proceeds), offsetting ongoing operating outflows. Management emphasized that this cash position supports clinical and operational activities into early 2027, providing runway beyond the anticipated late-2026 ALTITUDE-AD readout — a pivotal catalyst given the trial’s registration-quality design, 542-patient size, and focus on the iADRS primary endpoint alongside ARIA-E safety monitoring. The press release underscores sabirnetug’s mechanistic differentiation — selective targeting of toxic Aβ oligomers over plaques or monomers — supported by Phase 1 biomarker data showing rapid pTau181 and neurogranin improvements and a favorable ARIA-E profile, including no cases in ApoE4 homozygotes. Concurrently, the EBD™ program advancement — with an IND targeted for mid-2027 and near-term option exercise for up to two JCR candidates — signals strategic expansion beyond intravenous sabirnetug toward next-generation brain-penetrant oligomer therapeutics. Collectively, these disclosures reinforce Acumen’s positioning as a focused, cash-efficient clinical-stage player with a high-value near-term binary event and a de-risked pipeline extension path.